Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And the beat goes on...
Oh Canada! Drug Importation Bills Look North to Address Accessibility and Cost
By Sara W. Koblitz – (FDA Law Blog)
Speaking of Drug imports. Lower Canadian costs have gotten the most press and IMO could eventually lead the way to a more formalized agreement with US providers. Cheaper, yes. As safe, no, not yet, but brings to mind a post of mine last week (44484) regarding our Canadian DNA production patent and Canada's Optel Vision's 25% share of the serialization market. All speculation, but lowering high US drug prices is a big priority, more secure/safe Canadian Drugs (eventually others) and accessibility is certainly in the cards. Could we play a part in it? I think so.
Onto the Pharma front...
Chasm between WH and FDA on imports must be addressed. APDN is in a position I believe could sway the former commissioners and their cohorts into a compromise. Certainly a bridge building opporrtunity.
According to a “Final Report of the Defense Science Board (DSB) Task Force on Cyber Supply Chain”: http://www.acq.osd.mil/dsb/reports/2010s/DSB-CyberSupplyChainReport-Final.pdf
and a supplemental DAU review of it posted last week:
https://www.dau.mil/training/career-development/logistics/blog/Defense-Science-Board-Task-Force-Report-on-Cyber-Supply-Chain
My guess would be in relation piss-poor results of the past. Forgive me but at -50% over the last five years or so I'm a bit upset. GLTA
Okay Okay, I got an idea...
With under an hour to go. Go to your Windows(R) now, open 'em wide and yell "I'm not going to take it anymore!" Repeat... Maybe we see this thing close at 2, whatdoyasay?
LOL SOL...
As of this moment (2:37PM ET) our pps stands at 1.80 with volume just crossing 6K. What's up with that, I dont recall every seeing volume as low. Undecided votes prevail I presume...
Anyone have info/insight into that recent Canadian Patent (2713101) PR? Originally a Vandalia Application as a: METHOD FOR A CONTINUOUS RAPID THERMAL CYCLE SYSTEM, otherwise known as the biggest, bestest, fastest and cheapest method of DNA production.
http://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2713101/summary.html?query=2713101&start=1&num=50&type=basic_search
More curious since discovering Optel Vision (a Canadian Company) Leads the Pharmaceutical Serialization Industry with over a 25% Market Share. And like RFID "ready" solutions they offer, DNA seems a no brainer for them...
http://www.optelvision.com/news/optel-vision-leads-pharmaceutical-serialization-industry-biggest-market-share/#sthash.N7OZ7kNx.dpuf
Unless, as presumed, Signature T were introduced at the plant origin which then would authenticate the source. Our DNA is much more stable and can withstand processing much better than other DNA around it.
Not earth-shattering given recent reports like this one from Bloomberg in November...
Tests Show No Evidence of Aloe Vera in Some Aloe Vera Gels
A Bloomberg News investigation found that tests of store-brand aloe vera gel from CVS, Wal-Mart, and Target found no evidence they contained the substance.
None of these products require government testing or approval before they’re sold, Bloomberg notes:
Speaking of bondage, Ashton Kutcher recently testified before a Senate Foreign Relations Committee Hearing Ahead of END IT Movement’s Annual Shine a Light on Slavery Day.
DNA Tests Find Subway Chicken Only 50 Percent Meat, Canadian News Program Reports
http://www.npr.org/sections/thetwo-way/2017/03/01/517920680/dna-tests-find-subway-chicken-only-50-percent-meat-canadian-media-reports
Another "Forensic" solution. contested like hell by Subway. Needed: third party tie-breaker?
Good one, thanks Park. Endorsed and incorporated by CCL over two years ago! Not flyin' off the shelves, yet...
Curious why they're not among our Partners and Customer lineup, nor visible via a site search...
Excellent. Thanks RK. Looks like they're a one stop shop. I'd love to get the comps on the various solutions they offer...
Fake News?
Can't find that either.
I know that ITL Group, the label makers offer, amongst alternatives, our DNA as the only solution with a "100% Level of Security", but CCL? Wish I could find confirmation.
http://itl-group.com/2015/brand-protection/
CCL and APDN Connection?
Where, when? Perhaps they have been added to our Certified Printer Partners. Only "partners" I am aware of, from ADNAS site are: Creative Labels Inc,, Markem-Imaje, and DISC...
http://adnas.com/certified-printer-partners/
Related Blockchain PR
Blockchain technology first came to my attention regarding "Bitcoin's" adoption. As far as I can tell it is a software platform which facilitates financial transactions. Easy to Google, here's a bit from Bloomberg last August...
https://www.bloomberg.com/news/articles/2016-08-25/this-is-your-company-on-blockchain
Dont know of any connection to us..
New PR - Identifying Uzbek Cotton Biomarkers: A Proposed Collaborative Framework to Eliminate Forced Labor
Genetic markers for regional cultivars persist in cotton fibers and can be detected in our proprietary assay...
https://investorshub.advfn.com/secure/post_new.aspx?board_id=11976
Applied DNA Sciences Expands Patent Portfolio with a Range of Advancements that Enable Company's Continued Penetration of Core Business Verticals
New patents applicable to a broad range of markets, including pharmaceuticals and industrial products, among others
http://www.marketwired.com/press-release/applied-dna-sciences-expands-patent-portfolio-with-range-advancements-that-enable-companys-nasdaq-apdn-2197135.htm
STONY BROOK, NY--(Marketwired - February 21, 2017) - Applied DNA Sciences, Inc. ("Applied DNA") (NASDAQ: APDN) a provider of DNA-based supply-chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, is proud to announce a significant expansion of its U.S. and Global patent portfolio in 2016, demonstrating its ongoing commitment to innovation and leadership in the marketplace.
Applied DNA's U.S. and Global patent portfolio now totals 44 issued patents, with 84 applications pending. In 2016, Applied DNA was granted U.S. Patent Nos. 9,266,370, 9,290,819, 9,297,032, 9,412,284 and Canadian Patent No, 2,713,101. These newly issued patents provide broad long term protection for Applied DNA's core business verticals, including its fiberTyping, SigNature DNA, SigNature T and BackTrac platforms, as well as its bulk DNA production services.
U.S. Patent 9,290,819 is based upon Applied DNA's ground-breaking research in the genotyping of mature cotton fibers and provides strong protection of Applied DNA's fiberTyping services currently utilized by major U.S. retailers and brands as well as SigNature T supply chain partners. U.S. Patents 9,266,370 and 9,297,032 provide further protection for Applied DNA's SigNature DNA molecular taggant and the SigNature T platform, and their use in a broad range of markets, including, pharmaceuticals, consumer products, industrial materials, printing, and electronics. U.S. Patent 9,412,284 is the first in a new family of patents that protects the encoding and decoding of information within the 2-diminsional curves of a pattern, such as a military camouflage pattern. Canadian Patent No, 2,713,101 extends Applied DNA's protection of its unique bulk DNA production apparatus and methods to Canada.
Dr. James Hayward, president and CEO of Applied DNA, stated, "The continuous development of our intellectual property to advance the commercial adoption of our core technology platform, SigNature DNA, is central to our business model. These new patents and others under examination underpin our penetration of core business verticals with an uncopyable and unbreakable mark that can reduce risk and uncertainty across global supply chains. Our intellectual property estate is among our most valuable assets and we will look to further leverage this asset in the future."
Clay D. Shorrock, Esq., General Counsel for Applied DNA, stated: "Our commitment to innovation underpins our patent portfolio's strong growth in 2016. Our patents continue to validate our core technologies and confer a significant competitive advantage to the company. As we continue to innovate across our business lines, our patent portfolio is well positioned for substantial growth in 2017 and beyond."
Just trolling around the ADNAS site and noticed our next engagement on 2/15/17, The "Disruptive Growth Healthcare Conference" in NY. We were there last year, next week we're "1 on 1 Only", Day 1 (only).
http://www.meetmax.com/upload/event_40961/2017%20Disruptive%20Growth%20and%20Healthcare%20Conference%20Agenda%20as%20of%2010Feb%20FOR%20DISTRIBUTION.pdf
Decided to look a bit deeper into the more prominent players and found this one particularly upsetting. Shit happens...
Question Re: Delisting from NASDAQ?
Sure as hell would not qualify for up-listing at under $2 (as I recall). Anyone know for sure what to expect if we stay at $2ish for the next month or so? Chances of it?
"First Quarter Financial Highlights:
Revenues decreased 32% for the first quarter of fiscal 2017 to $903 thousand, compared with $1.32 million reported in the first quarter of fiscal 2016, and decreased 45% from the $1.64 million reported in the fourth fiscal quarter ended September 30, 2016. The year-over-year decrease in revenue is primarily attributable to a decrease in two government contract awards which both expired last quarter.
Total operating expenses were $4.6 million, compared with $4.1 million in the prior year's quarter, an increase of approximately $460 thousand or 11%. The increase in year-over-year total operating expenses is primarily attributable to an increase in SG&A primarily associated with stock option grants offset by decreases in legal and accounting fees, R&D expenses and decreased amortization and depreciation.
Net loss for the quarter ended December 31, 2016 was $4.0 million, or $0.16 per share, compared with a net loss of $2.9 million, or $0.13 per share for the quarter ended December 31, 2015 and a net loss of $2.4 million, or $0.10 per share for the quarter ended September 30, 2016.
Excluding non-cash expenses, Adjusted EBITDA for the quarter ended December 31, 2016 was negative $2.3 million compared to a negative Adjusted EBITDA of $2.2 million for the same quarter last year and a negative Adjusted EBITDA of $1.7 million in the prior fiscal quarter due mainly to a decrease in revenues. See below for information regarding non-GAAP measures.
Cash and cash equivalents as of December 31, 2016 totaled $6.7 million as compared to $4.5 million at September 30, 2016. The increase in cash balances is due primarily to a private placement completed last November 2016 which netted $4.3 million.
Net cash used in operating activities in the fiscal first quarter of 2017 was $2.1 million. This compares with $2.7 million the corresponding prior-year period."
http://www.marketwired.com/press-release/applied-dna-sciences-reports-fiscal-first-quarter-2017-financial-results-nasdaq-apdn-2194986.htm
Although historically those very PRs did little for our bottom line... could their absence perhaps indicate a surprise reversal of results reported last time around? You seem prepared for the worst, you may be right, but $500K?
"APDN reported a 4th Quarter September 2016 loss of $0.10 per share on revenue of $1.6 million. The consensus estimate was a loss of $0.06 per share on revenue of $3.0 million. Revenue fell 58.9% compared to the same quarter a year ago."
Fred, I have little doubt that our tech is superior to most, if not all, others. My point is there is a ton of competition. Fords, Chevys and Toyotas are good enough for most and certainly cheaper that an armored Phantom Coupé. Being the "Best" doesn't necessarily equate with broad acceptance or brand success, that's all. Hopefully we can make a buck in the balance.
Hurting, but still long...
Patents defendable? Competitive alternatives?
I'm not prepared to fork over $3500. for the full 83 page Technavio's report, but here are a couple of quotes from the summary: "Global Anti-Counterfeit Packaging Market 2017-2021". No details, but there doesn't seem to be any shortage of alternatives within the "packaging market"...
[quote]Key vendors
- Alien Technology
- AlpVision
- Avery Dennison
- SICPA
- Zebra Technologies
Other prominent vendors
- Advanced Track & Trace
- Advanced Traceability Solutions
- Aesica Pharmaceuticals
- Angstrom Technologies
- Applied DNA Sciences
- ATL Security Label Systems
- Atlantic Zeiser
- Authentix
- CFC International
- Colorcon
- Covectra
- Digimarc
- EM Microelectronic
- Essentra
- Everest Holovisions
- Flint Group
- Honeywell
- Impinj
- Ingenia Technology
- Interfarma
- Intermec
- International Ink
- Clarivate Analytics
- MicroTag Temed
- Morpho
- NanoGuardian
- NovaVision
- OpSec Security
- Prooftag
- ScanSource
- Schreiner ProSecure
- SCT International
- SMARTRAC
- Sun Chemical
- Systech
- TAGSYS
- Thermo Fisher Scientific
- TraceLink
- TruTag Technologies
- UPM Raflatac
- Verance
- Verayo
- WISeKey
- YottaMark
Market driver
- Demand from emerging nations.
Market challenge
- Inefficient anti-counterfeiting technologies.
Market trend
- Increase in adoption of chipless printable RFID technology
[/quote]
http://www.reportlinker.com/p02608403-summary/Global-Anti-counterfeit-Packaging-Market.html
CALL FOR ABSTRACTS
The 2017 Symposium On Counterfeit Parts And Materials (June 27-29).
http://www.calce.umd.edu/symposiums/SCEP2017/SCEP2017_mailer.html
I suspect we'll be there as usual. Seems much the same, although Scope to include:
"New areas of counterfeit concerns: materials, energy storage".
Should open our discussions to more than authentication of microchips. We'll see...
Enjoy the game.
The Future of Supply Chain Management
A good read
"Predicting the future of supply chain management is a fool’s game, but new find from CAPS Research gives a glimpse into how supply managers are preparing for tomorrow.
Another vertical to spend money on?
Given our core competencies, and our "Large-Scale DNA Production" capabilities I wonder if there is a potential niche.
Interesting sources...
The World's Ideal Storage Medium Is "Beyond Silicon"
http://www.evolutionnews.org/2017/01/the_worlds_idea103443.html
Also, from nature:
How DNA could store all the world’s data
http://www.nature.com/news/how-dna-could-store-all-the-world-s-data-1.20496
"Collaborative technology partnerships will play an important role in achieving greater supply chain visibility in the future". Partnerships, worth a look...
http://www.supplychainquarterly.com/news/scq20170120-next-generation-visibility-what-will-it-take-to-get-there/
Applied DNA Sciences Schedules Fiscal 2017 First Quarter Financial Results Conference Call and Webcast For Thursday, February 9, 2017 at 4:30 PM ET.
Sorry if repost, I just noticed.
Me thinks too, yet, perhaps in a more nuanced way, an enhancement to widely used RFID Requirements could be a significant entry point. It's deep roots are going great guns, and a "layered approach" seems to be a must.
Anti-counterfeit Beverage Packaging Market - Emergence Of Advanced
Technologies And Global Industry Analysis
Date: 01-23-2017 08:05 AM CET
Geez speed, step back. I for "one". On numerous occasions believe it or not. Your bias is showing...
I for one do, and I'm aware of others, I would certainly reccomend it.